Research · Sep 3, 2026
[NBIX] Neurocrine Biosciences Thesis 2026: Ingrezza Franchise Drives CRENESSITY Pediatric Launch
Neurocrine Biosciences Inc. (NASDAQ: NBIX) FY2025 revenue ~$2.55-2.75B (+15-25%) with adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza (valbenazine) revenue (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + selected various Huntington's chorea treatment) + selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment) + selected continued post-2024 selected ~$160-200M aggregate selected various royalties + selected various pipeline revenue under continued President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO). One of the world's leading neuroscience + endocrinology pharmaceutical companies. Founded 1992 as Neurocrine Biosciences in San Diego California by Wylie Vale + Joseph Schlessinger + Kevin Gorman + selected various Salk Institute researchers (~33-year heritage); selected post-1996 NASDAQ listing IPO; selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia; selected post-April 2024 Kyle Gano CEO appointment; selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval. Headquartered in San Diego California; ~1,400+ employees globally with ~$2.55-2.75B revenue. Two primary product + pipeline segments: Ingrezza Commercial (~90%+ ~$2.30-2.45B), CRENESSITY + Royalties + Pipeline (~10% ~$220-300M). Geographic mix: US ~95%+ + International ~5%. Ingrezza tardive dyskinesia franchise: ~$2.30-2.45B aggregate Ingrezza revenue FY2025; selected ~50%+ aggregate US tardive dyskinesia market share leadership; ~+15-20% YoY Ingrezza revenue growth. CRENESSITY (crinecerfont) CAH launch: post-December 2024 FDA approval; ~$200-400M aggregate FY2026 CRENESSITY revenue expectation; ~$0.40-0.60 incremental annual EPS contribution. President + CEO Kyle Gano since April 2024 (~1-year tenure); CFO Matt Abernethy. Capital + cash position: ~$300-500M aggregate FY2024-2025 buyback program (~$200-300M aggregate FY2025); aggregate capital return ~$200-300M; ~$1.6-1.9B aggregate cash + investments balance; ~$0M aggregate net debt position; selected pathway to dividend initiation FY2026-2027. FY2026 thesis: Ingrezza tardive dyskinesia franchise + CRENESSITY pediatric + adult CAH launch + ~50%+ aggregate US tardive dyskinesia market share leadership + ~$1.6-2.2B aggregate cash + investments balance + ~$0M aggregate net debt + ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027. Risks: Teva Austedo + tardive dyskinesia competition, US payer + reimbursement, CRENESSITY commercialization sustainability, clinical pipeline risk, Kyle Gano post-April 2024 strategic execution.